A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Study ID
NCT01676259

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

PROTACT

Trial Summary

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - ORR at 6 months.

More informations

Trial Starting Date

Mar 07,2018

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit